Automated segmentation of epicardial adipose tissue (EAT) and pericardial adipose tissue (PAT) in computed tomography (CT) has become a critical area in cardiovascular diagnosis. These fat deposits, separated by the pericardium, are closely linked to diseases such as ischemic heart disease, atrial fibrillation, and heart failure. However, traditional manual quantification is extremely labor-intensive and suffers from high inter-observer variability, limiting its clinical utility. Automated methods, based on both artificial intelligence and classical image processing techniques, offer a consistent and efficient solution, bringing these biomarkers closer to daily medical practice.
AI approaches, especially convolutional neural networks (CNNs) and transformers, have demonstrated accuracy comparable to human experts, even in scenarios with intravenous contrast where traditional attenuation thresholds fail. However, challenges remain: the need for larger annotated public datasets and optimized thresholds for contrast-enhanced CT. This is where specialized technological expertise makes a difference. Companies like Q2BSTUDIO are developing custom software applications that integrate segmentation models, verification workflows, and security protocols for sensitive data.
The integration of artificial intelligence into these systems enables not only automatic segmentation but also assisted decision-making. For example, AI agents can orchestrate the entire pipeline: from image acquisition to volumetric report generation, reducing the radiologist's workload. For these solutions to be scalable, a robust cloud infrastructure is required. Cloud AWS/Azure services provide the computational power needed to train models on large data volumes and deploy them in clinical environments, ensuring high availability and regulatory compliance.
Cybersecurity is another fundamental pillar. Patient data is protected by strict regulations (HIPAA, GDPR), and any software handling it must incorporate encryption, access control, and auditing. Q2BSTUDIO offers cybersecurity solutions that shield both the development and operation of these systems, preventing data leaks and ensuring clinical trust.
Once EAT and PAT volumes are obtained, the next step is data analysis and visualization. Business Intelligence (BI) tools like Power BI allow researchers and hospitals to correlate these biomarkers with clinical outcomes, create interactive dashboards, and detect population patterns. Integrating BI/Power BI into the segmentation platform transforms raw data into actionable information for medical and administrative decision-making.
AI agents, in turn, can automate repetitive tasks such as quality control of segmentations or model updating with new data. This not only accelerates the research cycle but also allows medical teams to focus on complex cases. The combination of all these technologies —developed as custom software by Q2BSTUDIO— is paving the way toward more accurate, personalized, and efficient cardiovascular diagnosis.
In conclusion, automated segmentation of cardiac adipose tissue in CT represents a significant advance, but its clinical implementation requires a solid technological ecosystem. Collaboration between medical imaging experts and development companies like Q2BSTUDIO, offering comprehensive services in AI, cloud, cybersecurity, and BI, is essential to overcome current barriers and bring these biomarkers to the patient. The future points to autonomous systems where AI agents manage the entire workflow, from acquisition to report, freeing clinicians to focus on what really matters: patient health.
